$CLRB
Cellectar Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Florham Park, NJ
CLRB chart
What traders are saying about $CLRB
Latest postsCellectar Biosciences, Inc. news
- Cellectar’s iopofosine case study shows complete response over 8 years
TipRanks ·
- Cellectar Biosciences Reports Durable Complete Response in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Quiver Quantitative ·
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Yahoo Finance ·
- One lymphoma patient had no disease progression for over eight years after one treatment.
Stock Titan ·
- Cellectar Biosciences, Inc. Estimates – NASDAQ:CLRB
TradingView ·
- CLRB Q3'26 Earnings: revenue estimate is 0 USD
TradingView ·
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Yahoo Finance ·
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Yahoo Finance ·
- Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
fool.com ·
- Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
Yahoo Finance ·
- Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary
app.moby.co ·
- Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Yahoo Finance ·
Cellectar Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$21.8M | -$44.6M | -$38.0M | -$31.8M |
| Diluted EPS | $-8.35 | $-41.89 | $-3.50 | $-4.51 |
| Total assets (year end) | $15.0M | $25.5M | $12.1M | $21.6M |
| Cash and equivalents (year end) | $13.2M | $23.3M | $9.6M | $19.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cellectar Biosciences, Inc.
- Ticker
- CLRB (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Florham Park, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
Frequently asked questions
What exchange is Cellectar Biosciences, Inc. listed on?
Cellectar Biosciences, Inc. trades on the Nasdaq under the ticker symbol CLRB.
What industry is Cellectar Biosciences, Inc. in?
Cellectar Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Cellectar Biosciences, Inc. headquartered?
Cellectar Biosciences, Inc.'s business address on file with the SEC is in Florham Park, NJ.
When does Cellectar Biosciences, Inc.'s fiscal year end?
Cellectar Biosciences, Inc.'s fiscal year ends on December 31.